SignalXSignalX

Tevogen Bio Holdings Inc. (TVGN) 8-K Current Report: March 4, 2026

Filed: March 4, 2026
Health Care
Biological Products, (No Diagnostic Substances)
Tevogen Bio Holdings Inc. Overview

Tevogen Bio Holdings Inc. (TVGN) 8-K current report filed with SEC EDGAR on March 4, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
3 items

  • Item 3.03: Material Modification to Rights of Security Holders
  • Item 5.03: Amendments to Articles of Incorporation or Bylaws
  • Item 7.01: Regulation FD Disclosure

Tevogen Bio Holdings Inc. 8-K Mar 4, 2026 Event Analysis

Item 3.03 · Material Modification to Rights of Security Holders

  • • Bylaws/charter amended — full details under Item 5.03 of this same 8-K filing
  • • Investors should review Item 5.03 for specifics on what shareholder rights or corporate governance provisions were changed

Item 5.03 · Amendments to Articles of Incorporation or Bylaws

  • • 1-for-50 reverse split effective March 6, 2026; reduces shares outstanding from ~202.4M to ~4.05M
  • • Authorized share count stays at 800M, dramatically increasing the ratio of authorized-to-outstanding shares — creates large future dilution capacity
  • • All warrants and convertible preferred adjusted proportionally: exercise/conversion prices multiplied by 50, share counts divided by 50
  • • Reverse split strongly signals Nasdaq minimum bid price compliance effort ($1.00 threshold), typical of companies under exchange delisting pressure
  • • Fractional shares cashed out at closing price on March 5, 2026 (pre-split adjusted); no new CUSIP risk — symbol TVGN unchanged

Item 7.01 · Regulation FD Disclosure

  • • Tevogen Bio (TVGN) announced a reverse stock split via press release dated March 4, 2026
  • • Reverse splits typically signal share price was below exchange minimum listing requirements — a red flag for shareholders
  • • Full terms (ratio, effective date) disclosed in Exhibit 99.1, not summarized in this item

Other Tevogen Bio Holdings Inc. 8-K Filings

8-K Feb 25, 2026

Get deeper insights on Tevogen Bio Holdings Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.